Literature DB >> 25944162

Association between donor and recipient smoothened gene polymorphisms and the risk of hepatocellular carcinoma recurrence following orthotopic liver transplantation in a Han Chinese population.

Pusen Wang1, Weiyong Song2, Hao Li1, Cunguang Wang1, Baojie Shi1, Wenzhi Guo3, Lin Zhong4.   

Abstract

Hepatocellular carcinoma (HCC) recurrence after orthotopic liver transplantation (OLT) is potential cause for the poor outcome. Smoothened (SMO) gene has been considered associating with HCC and HCC recurrence, but its association with HCC recurrence after OLT is not clear yet. In this study, we aim at evaluating the association between donor and recipient SMO gene polymorphisms and HCC recurrence after OLT. A total of 76 patients with HCC who had undergone OLT from July 2007 to August 2012 were included. A single nucleotide polymorphism (SNP), SMO rs3824, located at the 3'UTR region, was genotyped and analyzed in both donor and recipient. We demonstrated that recipient rs3824 polymorphism was significantly associated with HCC recurrence following OLT. In multivariate logistic regression analysis, TNM stage (p = 0.001), recipient SMO rs3824 genotype (CG vs. CC/GG p = 0.001), and histologic grade (p = 0.019) were identified as independent risk factors of HCC recurrence. Recurrence-free survival (RFS) and overall survival (OS) were significantly higher in the recipient CC/GG group than in the CG group (p = 0.003 and p = 0.011, respectively). Cox proportional hazards modeling revealed that TNM stage, recipient SMO rs3824 genotype, pre-OLT serum AFP level, and histologic grade were independent factors (p < 0.05) for patients' clinical outcomes. In conclusion, recipient SMO rs3824 polymorphism is associated with an increased risk of HCC recurrence following OLT and has a potential clinical value for the prognosis of HCC patients treated with OLT.

Entities:  

Keywords:  Hepatocellular carcinoma; Orthotopic liver transplantation; Prognosis; Recurrence; SMO polymorphism

Mesh:

Substances:

Year:  2015        PMID: 25944162     DOI: 10.1007/s13277-015-3370-x

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  29 in total

1.  World Medical Association declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects.

Authors: 
Journal:  JAMA       Date:  1997-03-19       Impact factor: 56.272

2.  Polymeric nanoparticle-encapsulated hedgehog pathway inhibitor HPI-1 (NanoHHI) inhibits systemic metastases in an orthotopic model of human hepatocellular carcinoma.

Authors:  Yang Xu; Venugopal Chenna; Chaoxin Hu; Hai-Xiang Sun; Mehtab Khan; Haibo Bai; Xin-Rong Yang; Qin-Feng Zhu; Yun-Fan Sun; Anirban Maitra; Jia Fan; Robert A Anders
Journal:  Clin Cancer Res       Date:  2011-08-25       Impact factor: 12.531

3.  Histological differentiation predicts post-liver transplantation survival time.

Authors:  Wen Xia Li; Zhao Li; Peng Ji Gao; Jie Gao; Ji Ye Zhu
Journal:  Clin Res Hepatol Gastroenterol       Date:  2013-12-30       Impact factor: 2.947

4.  Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival.

Authors:  F Y Yao; L Ferrell; N M Bass; J J Watson; P Bacchetti; A Venook; N L Ascher; J P Roberts
Journal:  Hepatology       Date:  2001-06       Impact factor: 17.425

5.  High expression of patched homolog-1 messenger RNA and glioma-associated oncogene-1 messenger RNA of sonic hedgehog signaling pathway indicates a risk of postresection recurrence of hepatocellular carcinoma.

Authors:  Kuo-Shyang Jeng; I-Shyan Sheen; Wen-Juei Jeng; Chien-Chu Lin; Chien-Kuan Lin; Jui-Chih Su; Ming-Che Yu; Hsin-Yi Fang
Journal:  Ann Surg Oncol       Date:  2012-08-22       Impact factor: 5.344

6.  Minimizing risk associated with elderly liver donors by matching to preferred recipients.

Authors:  Dorry L Segev; Warren R Maley; Christopher E Simpkins; Jayme E Locke; Geoffrey C Nguyen; Robert A Montgomery; Paul J Thuluvath
Journal:  Hepatology       Date:  2007-12       Impact factor: 17.425

7.  Donor Risk Index for African American liver transplant recipients with hepatitis C virus.

Authors:  Nathan J Shores; Jennifer L Dodge; Sandy Feng; Norah A Terrault
Journal:  Hepatology       Date:  2013-08-06       Impact factor: 17.425

8.  Smoothened (SMO) receptor mutations dictate resistance to vismodegib in basal cell carcinoma.

Authors:  Sabrina Pricl; Barbara Cortelazzi; Valentina Dal Col; Domenico Marson; Erik Laurini; Maurizio Fermeglia; Lisa Licitra; Silvana Pilotti; Paolo Bossi; Federica Perrone
Journal:  Mol Oncol       Date:  2014-09-26       Impact factor: 6.603

Review 9.  Targeting of Smoothened for therapeutic gain.

Authors:  Martial Ruat; Lucile Hoch; Hélène Faure; Didier Rognan
Journal:  Trends Pharmacol Sci       Date:  2014-04-01       Impact factor: 14.819

Review 10.  Liver transplantation for hepatocellular carcinoma.

Authors:  Vincenzo Mazzaferro; Yun Shin Chun; Ronnie T P Poon; Myron E Schwartz; Francis Y Yao; J Wallis Marsh; Sherrie Bhoori; Sung-Gyu Lee
Journal:  Ann Surg Oncol       Date:  2008-01-31       Impact factor: 5.344

View more
  5 in total

1.  Recipient C6 rs9200 genotype is associated with hepatocellular carcinoma recurrence after orthotopic liver transplantation in a Han Chinese population.

Authors:  Z Wang; J Liao; S Wu; C Li; J Fan; Z Peng
Journal:  Cancer Gene Ther       Date:  2016-05-13       Impact factor: 5.987

Review 2.  Emerging Roles of G Protein-Coupled Receptors in Hepatocellular Carcinoma.

Authors:  Wen-Ting Peng; Wu-Yi Sun; Xin-Ran Li; Jia-Chang Sun; Jia-Jia Du; Wei Wei
Journal:  Int J Mol Sci       Date:  2018-05-04       Impact factor: 5.923

3.  A small interfering RNA targeting vascular endothelial growth factor efficiently inhibits growth of VX2 cells and VX2 tumor model of hepatocellular carcinoma in rabbit by transarterial embolization-mediated siRNA delivery.

Authors:  Yu Zou; Chuan-Gen Guo; Zheng-Gang Yang; Jun-Hui Sun; Min-Ming Zhang; Cai-Yun Fu
Journal:  Drug Des Devel Ther       Date:  2016-03-24       Impact factor: 4.162

Review 4.  The Role of Smoothened in Cancer.

Authors:  Kuo-Shyang Jeng; I-Shyan Sheen; Chuen-Miin Leu; Ping-Hui Tseng; Chiung-Fang Chang
Journal:  Int J Mol Sci       Date:  2020-09-18       Impact factor: 5.923

5.  Albumin-bilirubin grade as a prognostic factor of hepatocellular carcinoma after treatment with orthotopic liver transplantation.

Authors:  Jianhua Liao; Jingting Liu; Changcan Li; Junwei Fan; Zhaowen Wang
Journal:  Transl Cancer Res       Date:  2019-08       Impact factor: 1.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.